Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call and Webcast

Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and
Year-End Financial Results Call and Webcast

CORAL GABLES, Fla., March 12, 2018 (GLOBE NEWSWIRE) -- Catalyst
Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on
developing and commercializing innovative therapies for people with rare
debilitating, chronic neuromuscular and neurological diseases, today announced
that it has changed the date for its fourth quarter and year-end financial
results conference call and webcast. Catalyst will now host its conference
call to discuss the financial results and to provide a corporate update at
5:00 p.m. ET on Wednesday, March 14, 2018. The conference call was previously
scheduled for Thursday, March 15^th at 8:30 a.m. ET.

The adjustment is being  made to accommodate  scheduling conflicts during  the 
originally  scheduled  time.  As  previously  announced,  fourth  quarter  and 
year-end 2017 financial results  will be released after  the market closes  on 
Wednesday, March 14, 2018.

Investors who wish to participate in the conference call may do so by  dialing 
(877) 407-8912  for  domestic  and  Canadian callers  or  (201)  689-8059  for 
international callers. Those  interested in listening  to the conference  call 
live via  the  internet may  do  so by  visiting  the Investors  page  of  the 
company's website at www.catalystpharma.com and clicking  on the webcast  link 
on the Investors home page.

A webcast  replay  will be  available  on the  Catalyst  website for  30  days 
following the call  by visiting  the Investor  page of  the company's  website 
at www.catalystpharma.com.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing
and commercializing innovative therapies for people with rare debilitating,
chronic neuromuscular and neurological diseases, including Lambert-Eaton
myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK
antibody positive myasthenia gravis, and infantile spasms. Firdapse® has
received Breakthrough Therapy Designation from the U.S. Food and Drug
Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for
LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug
in Europe for symptomatic treatment in adults with LEMS.

Catalyst is also developing CPP-115 to treat refractory infantile spasms.
CPP-115 has been granted U.S. Orphan Drug Designation for the treatment of
infantile spasms by the FDA and has been granted E.U. Orphan Medicinal Product
Designation for the treatment of West syndrome by the European Commission.  In
addition, Catalyst is developing a generic version of Sabril® (vigabatrin).

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which may cause
Catalyst's actual results in future periods to differ materially from
forecasted results. A number of factors, including those factors described in
Catalyst's Annual Report on Form 10-K for the fiscal year 2016 and its other
filings with the U.S. Securities and Exchange Commission (SEC), could
adversely affect Catalyst. Copies of Catalyst's filings with the SEC are
available from the SEC, may be found on Catalyst's website or may be obtained
upon request from Catalyst. Catalyst does not undertake any obligation to
update the information contained herein, which speaks only as of this date.

Investor Contact
Brian Korb
The Trout Group LLC
(646) 378-2923
bkorb@troutgroup.com

Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com

Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com

Primary Logo
Press spacebar to pause and continue. Press esc to stop.